{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:11:41Z","timestamp":1792239101618,"version":"4.4.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Talquetamab, a G protein\u2013coupled receptor class C group 5 member D\u2013targeting bispecific antibody for relapsed\/refractory multiple myeloma (R\/R MM), plus daratumumab, may lead to deeper and more durable responses than either therapy alone. In the phase 1b TRIMM-2 study, patients with R\/R MM (at least 3 previous lines of therapy or double refractory to a proteasome inhibitor and an immunomodulatory drug) received subcutaneous talquetamab 0.4 mg\/kg weekly (QW; \u201cQW cohort\u201d) or 0.8 mg\/kg every other week (Q2W cohort) plus daratumumab 1800 mg per the approved schedule. The primary end point was safety. Secondary end points included overall response and duration of response. Progression-free survival was an exploratory end point. Sixty-five patients (median 5 previous lines of therapy; 61.5% triple-class refractory; 24.6% bispecific antibody exposed) received talquetamab plus daratumumab (QW, n = 14; Q2W, n = 51; median follow-up of 18.6 months). Most common adverse events were oral events, skin events, cytokine release syndrome, and infections. Grade 3 or 4 events occurred in 81.5%. Two patients had dose-limiting toxicities, both in the Q2W cohort (grade 3 stomatitis\/oral mucositis, and grade 3 maculopapular rash). Responses occurred in 71.4% (QW cohort) and 82.4% (Q2W cohort) of patients. Median progression-free survival was 23.3 and 21.2 months, respectively, in each cohort. Pharmacodynamic results suggest the immunomodulatory action of daratumumab contributes to a conducive environment for talquetamab by reducing immunosuppressive cells. Talquetamab plus daratumumab demonstrated promising efficacy outcomes in patients with heavily pretreated disease, with a safety profile consistent with each agent as monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT04108195.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029360","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:54:46Z","timestamp":1758578086000},"page":"2902-2913","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study"],"prefix":"10.1182","volume":"146","author":[{"given":"Ajai","family":"Chari","sequence":"first","affiliation":[{"name":"1Department of Hematology Oncology\/Myeloma, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"3Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"4Department of Oncology, Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Centro de Investigaci\u00f3n del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Clinic Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-9813","authenticated-orcid":false,"given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[{"name":"1Department of Hematology Oncology\/Myeloma, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morillo","sequence":"additional","affiliation":[{"name":"7Department of Hematology, University Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, START Madrid-FJD Early-Phase Unit, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[{"name":"8Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[{"name":"9Central Unit for Clinical Trials, Cl\u00ednica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9019-7438","authenticated-orcid":false,"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Medical Oncology (Cancer), Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2221","authenticated-orcid":false,"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"12Clinical Research Support Unit, Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"13Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"14Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[{"name":"15Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Skerget","sequence":"additional","affiliation":[{"name":"15Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-4341","authenticated-orcid":false,"given":"Raluca I.","family":"Verona","sequence":"additional","affiliation":[{"name":"15Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Bakshi","sequence":"additional","affiliation":[{"name":"15Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Kang","sequence":"additional","affiliation":[{"name":"15Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5220-7730","authenticated-orcid":false,"given":"Thomas J.","family":"Prior","sequence":"additional","affiliation":[{"name":"15Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien","family":"Vandenberk","sequence":"additional","affiliation":[{"name":"16Johnson & Johnson, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaszianne","family":"Tolbert","sequence":"additional","affiliation":[{"name":"15Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangmin","family":"Lee","sequence":"additional","affiliation":[{"name":"15Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Damiette","family":"Smit","sequence":"additional","affiliation":[{"name":"17Johnson & Johnson, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-3444","authenticated-orcid":false,"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[{"name":"18Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2025121111214490300_bib1","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Talquetamab, a T-cell redirecting GPRC5DxCD3 bispecific antibody for patients with relapsed\/refractory multiple myeloma: pivotal phase 1\/2 safety and efficacy results from MonumenTAL-1","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Hematol"},{"issue":"10297","key":"2025121111214490300_bib2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"2025121111214490300_bib3","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2025121111214490300_bib4","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"22","key":"2025121111214490300_bib5","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"issue":"6","key":"2025121111214490300_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"2025121111214490300_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10301","key":"2025121111214490300_bib8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"2025121111214490300_bib9","author":"Schinke","year":"2-6  2023"},{"issue":"8","key":"2025121111214490300_bib10","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2025121111214490300_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab","volume":"24","author":"Chari","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025121111214490300_bib12","author":"Rodr\u00edguez-Otero","year":"2-6  2023"},{"issue":"14","key":"2025121111214490300_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2025121111214490300_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2025121111214490300_bib15","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"21","key":"2025121111214490300_bib16","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"10027","key":"2025121111214490300_bib17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"2025121111214490300_bib18","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025121111214490300_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025121111214490300_bib20","author":"Ma","year":"10-12  2023"},{"key":"2025121111214490300_bib21","author":"Chari","year":"9-12  2023"},{"issue":"suppl 16","key":"2025121111214490300_bib22","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025121111214490300_bib23","author":"Matous","year":"9-12  2023"},{"issue":"6","key":"2025121111214490300_bib24","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025121111214490300_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"2025121111214490300_bib26","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ejh.13942","article-title":"Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma","volume":"110","author":"Abdallah","year":"2023","journal-title":"Eur J Haematol"},{"issue":"21","key":"2025121111214490300_bib27","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","article-title":"CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"Perez de Acha","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025121111214490300_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study [abstract]","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2025121111214490300_bib29","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121111214490300_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.HS9.0000843612.41180.42","article-title":"RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed\/refractory multiple myeloma: preliminary results from a first-in-human trial","volume":"6","author":"Hasselbalch Riley","year":"2022","journal-title":"HemaSphere"},{"issue":"2","key":"2025121111214490300_bib31","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"}],"updated-by":[{"DOI":"10.1182\/blood.2026034830","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/24\/2902\/2471059\/blood_bld-2025-029360-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/24\/2902\/2471059\/blood_bld-2025-029360-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:21:52Z","timestamp":1765470112000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/24\/2902\/547408\/Talquetamab-plus-daratumumab-for-the-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":31,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029360","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,11]]},"published":{"date-parts":[[2025,12,11]]}}}